The prediction of early progressive disease in patients with hepatocellular carcinoma receiving atezolizumab plus bevacizumab

The prediction of early progressive disease in patients with hepatocellular carcinoma receiving atezolizumab plus bevacizumab

Abstract Background and Aims The IMbrave 150 trial revealed the usefulness of atezolizumab plus bevacizumab therapy in patients with unresectable hepatocellular carcinoma (HCC), making it now considered the first‐line systemic chemotherapy agent for HCC. The present study investigated factors associ...

Full description

Bibliographic Details
Main Authors: Yasuto Takeuchi, Kazuhiro Nouso, Shin‐ichi Fujioka, Kazuya Kariyama, Haruhiko Kobashi, Shuji Uematsu, Akio Moriya, Hiroaki Hagihara, Hiroyuki Takabatake, Shinichiro Nakamura, Kazuhisa Yabushita, Tatsuya Kikuchi, Atsushi Oyama, Takuya Adachi, Nozomu Wada, Hideki Onishi, Hidenori Shiraha, Akinobu Takaki
Format: Article
Language:English
Published: Wiley 2023-09-01
Series:Cancer Medicine
Subjects:
atezolizumab
bevacizumab
early progression
hepatocellular carcinoma
real‐world practice
Online Access:https://doi.org/10.1002/cam4.6369

Internet

https://doi.org/10.1002/cam4.6369

Similar Items